CTSOEarnings•prnewswire•
Citius Oncology, Inc. Reports Fiscal Third Quarter 2025 Financial Results and Provides Business Update
Sentiment:Neutral (40)
Summary
LYMPHIR commercial availability planned for the fourth quarter of 2025 $12.5 million in gross financings raised during the quarter by Citius Pharmaceuticals, with an additional $9 million raised by Citius Oncology in July 2025, to facilitate LYMPHIR pre-launch initiatives and drive...
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on August 12, 2025 by prnewswire